Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-α expression in breast cancer cells

Molecular Cancer Research

Volumn 6, Issue 8, 2008, Pages 1347-1355

  Han, Youqi ^a   Yang, Lin ^a   Suarez Saiz, Fernando ^a   San Marina, Serban ^a   Cui, Jie ^a   Minden, Mark D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; SHORT HAIRPIN RNA; TAMOXIFEN; WT1 PROTEIN; ESR1 PROTEIN, HUMAN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; BINDING SITE; BREAST TUMOR; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR GENE;

ANIMALS; APOPTOSIS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CONSENSUS SEQUENCE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, NEOPLASM; MICE; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; TAMOXIFEN; TRANSCRIPTION, GENETIC; TRANSFECTION; WT1 PROTEINS;

EID: 52449108275     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2179     Document Type: Article

References (39)

1. Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol 2005;20:343-60.
2. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001;29:2905-19.
3. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003;22:7316-39.
4. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-77.
5. Swain SM. Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clin Oncol 2001;19:93-7S.
6. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273:141-61.
7. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167-71.
8. Karakas T, Miething CC, Maurer U, et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002;16:846-54.
9. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
10. Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM. Down-regulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 2002;295:784-90.
11. Madden SL, Cook DM, Rauscher FJ III. A structure-function analysis of transcriptional repression mediated by the WT1, Wilms' tumor suppressor protein. Oncogene 1993;8:1713-20.
12. Reddy JC, Licht JD. The WT1 Wilms' tumor suppressor gene: how much do we really know? Biochim Biophys Acta 1996;1287:1-28.
13. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
14. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A 1991;88:9618-22.
15. Telerman A, Dodemont H, Degraef C, et al. Identification of the cellular protein encoded by the human Wilms' tumor (WT1) gene. Oncogene 1992;7:2545-8.
16. Silberstein GB, Van Horn K, Strickland P, Roberts CT, Jr., Daniel CW. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U S A 1997;94:8132-7.
17. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
18. Rickard DJ, Waters KM, Ruesink TJ, et al. Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J Bone Miner Res 2002;17:580-92.
19. Charpentier AH, Bednarek AK, Daniel RL, et al. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 2000;60:5977-83.
20. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC. Anatomy of the estrogen response element. Trends Endocrinol Metab 2004;15:73-8.
21. Clarke R, Skaar T, Baumann K, et al. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat 1994;31:237-48.
22. Kos M, Reid G, Denger S, Gannon F. Minireview: genomic organization of the human ERA gene promoter region. Mol Endocrinol 2001;15:2057-63.
23. Perou CM, Jeffrey SS, van de RM, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-7.
24. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
25. Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic information and estrogen receptor α expression in breast cancer. Oncologist 2006;11:1-8.
26. McKeage K, Curran MP, Plosker GL. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs 2004;64:633-48.
27. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M. How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 2003;10:261-6.
28. Adams PD, Cairns P. Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells. Cancer Biol Ther 2003;2:557-8.
29. Allred DC, Brown P, Medina D. The origins of estrogen receptor α-positive and estrogen receptor α-negative human breast cancer. Breast Cancer Res 2004;6:240-5.
30. Archey WB, McEachern KA, Robson M, et al. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 2002;21:7034-41.
31. Monks NR, Pardee AB. Targeting the NF-κB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs. J Cell Biochem 2006;98:221-33.
32. Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep 2005;14:337-43.
33. Kim SJ, Kim TW, Lee SY, et al. CpG methylation of the ERα and ERβ genes in breast cancer. Int J Mol Med 2004;14:289-93.
34. Macaluso M, Montanari M, Giordano A. The regulation of ER-{α} transcription by pRb2/p130 in breast cancer. Ann Oncol 2005;16 Suppl 4:iv20-22.
35. Singh RR, Barnes CJ, Talukder AH, Fuqua SA, Kumar R. Negative regulation of estrogen receptor α transactivation functions by LIM domain only 4 protein. Cancer Res 2005;65:10594-601.
36. Reizner N, Maor S, Sarfstein R, et al. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-α and regulates IGF-I receptor gene transcription in breast cancer cells. J Mol Endocrinol 2005;35:135-44.
37. Han Y, San Marina S, Liu J, Minden MD. Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene 2004;23:6933-41.
38. deConinck EC, McPherson LA, Weigel RJ. Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol 1995;15:2191-6.
39. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.